HOME
PRODUCTS
COMPANY
CONTACT
FAQ
Research
Dictionary
Pharma
Sign Up
FREE
or
Login
Username:
Password:
Remember login
Login
Send password reminder...
M 16287
structure given in first source
Also Known As:
1-(3-chlorobenzo(b)furan-2-ylsulfonyl)hydantoin; M-16287; M16287; 2,4-Imidazolidinedione, 1-((3-chloro-2-benzofuranyl)sulfonyl)-
Networked:
3
relevant articles (
2
outcomes,
1
trials/studies)
Relationship Network
Bio-Agent Context: Research Results
Heterocyclic Compounds: 198
1-Ring Heterocyclic Compounds
Azoles: 2138
Imidazoles: 150
Imidazolidines: 39
Hydantoins: 306
M 16287: 3
Fused-Ring Heterocyclic Compounds
2-Ring Heterocyclic Compounds
Benzofurans: 26
M 16287: 3
Related Diseases
1.
Diabetes Complications
02/07/1991 - "
The present study indicates that M16209 and M16287 are potent aldose reductase inhibitors expected to be useful for the treatment of diabetic complications.
"
06/01/1991 - "
These results indicate that M16209 and M16287 are potent aldose reductase inhibitors, which could be applicable to treatment for diabetic complications.
"
12/01/1990 - "
These results indicate that M16209 and M16287 can prevent galactose-induced cataract formation through amelioration of metabolic disorders and thus have high potential for clinical use in the treatment of some diabetic complications.
"
2.
Diabetic Neuropathies (Diabetic Neuropathy)
02/07/1991 - "
Effects of novel aldose reductase inhibitors, M16209 and M16287, on streptozotocin-induced diabetic neuropathy in rats.
"
06/01/1991 - "
M16209 and M16287 were effective in the prevention of galactosemic cataracts and amelioration of diabetic neuropathy with almost the same potency, while ONO-2235 was effective only in neuropathy, and sorbinil was effective in galactosemic cataracts and diabetic neuropathy with a different potency.
"
3.
Cataract (Cataracts)
12/01/1990 - "
These results indicate that M16209 and M16287 can prevent galactose-induced cataract formation through amelioration of metabolic disorders and thus have high potential for clinical use in the treatment of some diabetic complications.
"
06/01/1991 - "
M16209 and M16287 were effective in the prevention of galactosemic cataracts and amelioration of diabetic neuropathy with almost the same potency, while ONO-2235 was effective only in neuropathy, and sorbinil was effective in galactosemic cataracts and diabetic neuropathy with a different potency.
"
12/01/1990 - "
Effects of novel aldose reductase inhibitors, M16209 (1-(3-bromobenzo[b]furan-2-ylsulfonyl)hydantoin) and M16287 (1-(3-chlorobenzo[b]furan-2-ylsulfonyl)hydantoin), on galactose-induced cataract formation in rats were investigated.
"
Related Drugs and Biologics
1.
M 16209
2.
Aldehyde Reductase (Aldose Reductase)
3.
epalrestat
4.
sorbinil
5.
Streptozocin (Streptozotocin)
6.
Hydantoins
7.
Galactose (Galactopyranose)
8.
furan